Mesoblast offers an extraordinary gap between current price and analyst consensus — over 116% potential upside at roughly 34-to-1 reward versus geometric downside — but the stock is in a falling-knife formation, burns cash at over 100% of revenues, operates with zero reported margins, and quality scores well below minimum thresholds; the asymmetric geometry is notable but the entry setup is not confirmed.
Thesis pillars
- Cash Burn Zero Margin Profile→Stable
- Extreme Asymmetric Upside Geometry→Stable
- Falling Knife Technical Profile→Stable
- +1 more pillar — see the Why tab for full reasoning
Mesoblast Limited (MESO) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $13.79, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers... Read more
Hold if already holding. Not a fresh buy at $13.79, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum. Chart setup: Death cross, below all MAs, RSI 31, MACD bearish. Mixed signals. Hold existing position. Score 5.8/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 134d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-10-15Recent Developments — Mesoblast Limited
Latest news
- NEWS Mesoblast beats revenue estimates but posts Q3 loss, plans adult expansion for RYONCIL therapy. - Pluang — Pluang positive
- NEWS Mesoblast Receives FDA Approval To Implement A New Potency Assay, T-Cell Proliferation Inhibition Bioassay, For Release — benzinga Sep 24, 2026 positive
- NEWS Piper Sandler Reiterates Overweight on Mesoblast, Raises Price Target to $39 — benzinga Aug 27, 2026 positive
- NEWS Mesoblast FY EPS $(0.04) Misses $0.01 Estimate, Sales $120.250M Beat $66.000M Estimate — benzinga Aug 27, 2026 positive
- NEWS Reported Earlier, Mesoblast Reports FY2026 Total Revenue Of $120.3M Up From $17.2M, Net Loss Narrows 44% To $57.5M From — benzinga Aug 27, 2026 positive
Generated 2026-10-15T11:37:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $13.79, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum. Chart setup: Death cross, below all MAs, RSI 31, MACD bearish. Mixed signals. Hold existing position. Target $31.45 (+128.1%), stop $13.01 (−6.0%), A.R:R 20.2:1. Score 5.8/10, moderate confidence.
Take-profit target: $31.45 (+128.1% upside). Target $31.45 (+128.1%), stop $13.01 (−6.0%), A.R:R 20.2:1. Stop-loss: $13.01.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Negative momentum; Below 200-MA, MA slope -2.1%/30d (confirmed downtrend).
Mesoblast Limited trades at a P/E of N/A (forward 30.5). TrendMatrix value score: 4.2/10. Verdict: Hold.
10 analysts cover MESO with a consensus score of 4.1/5. Average price target: $37.
What does Mesoblast Limited do?Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in...
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.